Lunit has collaborated with Roche to improve precision medicine and improve cancer biomarker testing.
Luni’s AI-powered tool, Lunit SCOPE PD-L1 22C3 TPS, is integrated into Roche's navify Digital Pathology platform.
This partnership represents the first deployment of Lunit's AI technology with Roche, aiming to provide pathologists and scientists with advanced tools for cancer research and diagnostics.
Roche's navify Digital Pathology now features a suite of AI-driven algorithms, including Lunit SCOPE.
This integration facilitates access to external innovations and aims to improve biomarker testing for cancer research, potentially leading to better patient outcomes through precision medicine.
The collaboration has a broad geographic reach, initially launching in the US and planning future expansions to Canada, the European Union (including the UK), South Korea, and Japan.
The strategic move is designed to enhance cancer diagnostics and treatment across various healthcare markets worldwide.
The Lunit SCOPE PD-L1 22C3 TPS leverages AI to provide valuable insights and analysis of the PD-L1 tumour proportion score (TPS), an essential biomarker in cancer immunotherapy.
By automating the PD-L1 scoring process, the AI tool offers more consistent, accurate, and efficient assessments, which is particularly beneficial for a challenging biomarker such as PD-L1 TPS.
Since 2021, Lunit SCOPE PD-L1 has been available for research use only.
Lunit said the integration into Roche's navify platform will maximise access to this AI technology.
Lunit CEO Brandon Suh said: “We're thrilled to work together with Roche within its open digital pathology ecosystem, which we believe will create powerful synergies and represent a significant step toward making Lunit's AI tools accessible globally.
“Today, we have made PD-L1 analysis available, and we look forward to sharing more of our tools on this platform in the future. By integrating our precise and reliable algorithms, we aim to accelerate the advancement of precision medicine, enhancing workflow efficiency and introducing new biomarkers for improved patient care.”
In December 2023, Lunit agreed to acquire Volpara Health Technologies in a deal valued A$292m ($193m).
